Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30379007 | 0.90 | TSHR (0.42) | BRD4TSHRMEN1MAPTKMT2A | |
| SCHEMBL29220788 | 0.90 | TSHR (0.42) | BRD4TSHRMEN1MAPTKMT2A | |
| SCHEMBL26091936 | 0.85 | BRD4 (0.49) | BRD4TSHRGRM2SCN9AKCNH2 | |
| SCHEMBL26089096 | 0.83 | ALDH1A1 (0.51) | BRD4MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL30378591 | 0.83 | ALDH1A1 (0.51) | BRD4MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL21765659 | 0.82 | TSHR (0.52) | BRD4TSHRMEN1MAPTKMT2A | |
| SCHEMBL30910079 | 0.81 | ALDH1A1 (0.42) | BRD4TSHRMEN1MAPTKMT2A | |
| SCHEMBL26091592 | 0.81 | ALDH1A1 (0.42) | BRD4TSHRMEN1MAPTKMT2A | |
| SCHEMBL29220800 | 0.81 | BRD4 (0.43) | BRD4TSHRMAPTGRM2ALDH1A1 | |
| SCHEMBL30910160 | 0.81 | BRD4 (0.43) | BRD4TSHRMAPTGRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SAPIENSBIO INC. (KR) | 2025-01-02 | — | — | US | disclosed |
| EP-4421070-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sapiensbio Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| CN-118119612-A | Novel compounds and pharmaceutical compositions comprising the same | 萨皮恩斯生物有限公司 | 2024-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | RHOA, ACTR2, MFAP1 | BRD4 371/4885TSHR 4875/4885MEN1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.